USFDA issues import alert on Ratlam facility of Ipca Lab

January 23, 2015 11:02 pm | Updated 11:02 pm IST - NEW DELHI:

The U.S. health regulator has issued import alert on drugs produced at the Ratlam facility of Ipca Laboratories in Madhya Pradesh, following which the company has suspended shipment of active pharmaceutical ingredients to the American market.

“We now wish to inform you that the U.S. Food and Drug Administration (USFDA) has issued an import alert to the said manufacturing facility (Ratlam ) on January 22,” Ipca Laboratories said in a filing to the BSE.

Consequently, the company has voluntarily decided to temporarily suspend API (active pharmaceutical ingredients) shipments from this manufacturing facility for the U.S. markets till this issue is addressed, it added.

Under the import alert, authorities can detain without physical examination of unapproved new drugs promoted in the U.S.

The development follows an inspection at the company’s API manufacturing unit at Ratlam by the USFDA officials, who had made certain inspection observations in Form 483, it added.

Under Form 483, USFDA officials communicate the concerns related to non-compliance of manufacturing norms discovered during inspections at manufacturing units. But it is not a final observation from the U.S. health regulator.

However, four API’s — Hydroxychloroquine Sulfate, Propanolol Hydrochloride, Trimethoprim and Ondansetron — manufactured at the said manufacturing facility are excluded from the import alert, it added.

Shares tank over 8 % Shares of Ipca Laboratories ended with a steep loss of over 8 per cent on Friday. After plunging 8.9 per cent to Rs.637 intra-day trade on the BSE, shares of Ipca Lab finally ended at Rs.639.15, down 8.60 per cent from the previous close.

At the NSE, the stock slumped by 8.74 per cent to close at Rs.637.85.

The company’s market value tumbled Rs.760.84 crore to Rs.8,064.16 crore.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.